Kristina Lo
Contact:
kmlo@ucdavis.edu

Titles:
Staff Pharmacist II, UCD Health, Oncology Specialty Pharmacist

Education:
PharmD., The Daniel K. Inouye College of Pharmacy, Hilo, HI, 2015

Post-graduate Training:

  • PGY1 Pharmacy Practice Residency, UC San Diego Health, 2015-2016
  • PGY2 Hematology/Oncology Residency, UC Davis Medical Center, 2016-2017

Research Interests:
New agents: oral anti-cancer therapy agents, non-malignant hematologic oral therapies,  oral chemotherapy, oral anti-cancer adherence

Practice Philosophy:
I have always been fascinated with the world of oncology. It is my belief that patients diagnosed with a hematologic/oncologic malignancy are amongst the most complicated and require a comprehensive approach to care. With so many different diagnoses and approved therapies, pharmacists play a large role in patients’ comprehensive care from patient education on the many risks of their cancer therapy to lab monitoring for expected toxicities of therapy. We must be champions of continuing education as new anti-cancer agents are being approved every day. While it is exciting to have so many new treatment options, we must at the same time be attentive to the supportive data as it applies to each individual patient and make evidence driven recommendations and decisions.

Rotations Precepted:
Specialty Oncology Pharmacy (PGY1 and PGY2)

Bio:
Dr. Kristina Lo is board certified in Hematology/Oncology. She is currently a Staff Pharmacist at UC Davis Health in the UC Davis Cancer Center. At The Daniel K. Inouye College of Pharmacy, she was the recipient of the Mylan Institute Pharmacy Excellency Award. She went on to complete a PGY1 Pharmacy Practice Residency at UC San Diego Health in 2016 and PGY2 Hematology/Oncology Residency at UC Davis Health in 2017.

Following completion of her PGY2 she accepted a position with UC Davis Health in the Oncology Specialty Pharmacy where she manages patients who are prescribed oral anti-cancer agents. In this pharmacist-driven outpatient clinic, she focuses on providing comprehensive management of patients diagnosed with a hematologic/oncologic malignancy on an oral anti-cancer therapy. Care includes but is not limited to: medication adherence follow-up, management of toxicities due to anti-cancer agents, oncologic supportive care, and financial support for oral anti-cancer agents.